106561-29-9

Usage

Uses

Used in Pharmaceutical Industry:
Furo[2,3-d]pyrimidin-4(1H)-one, 5,6-diphenylis used as a potential pharmaceutical candidate for its unique structure and potential biological activities. Its specific properties and applications may be revealed through further research and study, making it a promising compound for the development of new drugs and therapies.
Used in Medicinal Chemistry:
Furo[2,3-d]pyrimidin-4(1H)-one, 5,6-diphenylis used as a compound of interest in medicinal chemistry for its potential to contribute to the discovery and design of novel therapeutic agents. Its unique structure and potential biological activities may offer new avenues for the treatment of various diseases and conditions.

Upstream product

• 5503-73-1 2-amino-3-cyano-4,5-diphenylfuran 
• 119-53-9 2-hydroxy-2-phenylacetophenone 
• 108-24-7 acetic anhydride 
• 1484-49-7 ethyl 2-amino-4,5-diphenyl-furan-3-carboxylate 
• 77287-34-4 formamide 
• 107833-28-3 N-(3-cyano-4,5-diphenylfuran-2-yl)formamide 
• 64-18-6 formic acid 

Downstream Products

• 65148-07-4 4-chloro-5,6-diphenylfuro[2,3-d]pyrimidine 
• 873306-32-2 4-bromo-5,6-diphenyl-furo[2,3-d]pyrimidine 

Relevant academic research and scientific papers

METHODS FOR THE TREATMENT OF DISORDERS RELATED TO PHOSPHORYLATION OF HISTONES

Methods for disease diagnosis, prognosis and therapy selection. Compositions for use in these methods and selected therapies for treatment are also disclosed.

Novel, Cyclically Substituted Furopyrimidine Derivatives and Use Thereof

The present application relates to novel, cyclically substituted furopyrimidine derivatives, methods for their production, their use for the treatment and/or prophylaxis of diseases and their use for the production of medicinal products for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular diseases.

Identification, SAR studies, and X-ray Co-crystallographic analysis of a novel furanopyrimidine aurora kinase a inhibitor

Herein we reveal a simple method for the identification of novel Aurora kinase A inhibitors through substructure searching of an in-house compound library to select compounds for testing. A hydrazone fragment conferring Aurora kinase activity and heterocy

Fused Bicyclic and Tricyclic Pyrimidine Compounds as Tyrosine Kinase Inhibitors

Fused bicyclic or tricyclic compounds of formula (I): wherein A, B, C, X, Y, m, and n are defined herein. Also disclosed are a method for inhibiting EGFR kinase activity and a method for treating cancer with these compounds.

Synthesis, characterization and antimicrobial evaluation of some arylidenehy drazon of uropyrimidines and thienopyrimidines

Cyclization of hetcroaromatic o-aminoestcr with formamide afforded furo[2, 3-d]pyrimidin-4(3II)-one which was then chlorinated with thionyl chloride followed by displacement by hydrazine hydrate to furnish hydrazinofuro [2, 3-d]pyrimidine. Reaction of hydrazino derivative with formic acid gave furo[3, 2-c][ 1, 2, 4]triazolo[4, 3-c]pyrimidine. Treatment of hydrazino derivative with aromatic aldehydes afforded arylidenehydrazonofuro[2, 3-d]pyrimidine derivatives. Reaction of o-aminonitrile with carbon disulphide, followed by methylation with methyl iodide and subsequent reaction with hydrazine hydrate afforded hydrazinothieno[2, 3-d]pyrimidine. 14 derivatives were synthesized. Some of these derivatives exhibited pronounced antimicrobial activities against S. typhi, S. aureus, S. dysenteriae, V. cholerae, C. lunata, A. alternata, C. corchori, F. equeseti and M. phaseolina.

FUSED BICYCLIC PYRIMIDINE COMPOUNDS AS AURORA KINASE INHIBITORS

Fused bicyclic pyrimidine compounds of formula (I): wherein R1, R3, R4, X1, X2, Y, Z, A, B, C, D, n, and the two bonds are defined herein. Also disclosed are a method for inhibiting Aurora kinase activity and a method for treating cancer with these compounds.

FURANOPYRIMIDINES

The present invention relates to furanopyrimidine compounds having the general Formula (I) and stereoisomers, tautomers, solvates, pharmaceutically acceptable salts and derivatives, and prodrugs thereof. The invention also includes pharmaceutical compositions comprising a compound of Formula (I), methods of treating various diseases and conditions in a mammal, including inflammation, inhibition of T cell activation, proliferation, arthritis, organ transplant, ischemic or reperfusion injury, myocardial infarction, stroke, multiple sclerosis, inflammatory bowel disease, Crohn's disease, lupus, hypersensitivity, type 1 diabetes, psoriasis, dermatitis, Hashimoto's thyroiditis, Sjogren's syndrome, autoimmune hyperthyroidism, Addison's disease, autoimmune diseases, glomerulonephritis, allergic diseases, asthma, hayfever, eczema, cancer, colon carcinoma and thymoma, comprising administering to the mammal a therapeutically effective amount of a compound of Formula (I). The invention also relates to methods of manufacturing medicaments, which comprise one or more compounds of Formula (I).

Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases

Described herein are compounds and compositions for modulating kinase activity, and methods for modulating kinase activity using the compounds and compositions. Also described herein are methods of using the compounds and/or compositions in the treatment

Fused pyrimidines. Part II: Synthesis and antimicrobial activity of some furo[3,2-e]imidazo[1,2-c]pyrimidines and furo[2,3-d]pyrimidines

2-Amino-4,5-diphenylfuran-3-carbonitrile (2) reacted with N-[bis(methylthio)methylene]glycine ethyl ester (1) to afford a double cyclized product 5-methylthio-8,9-diphenylfuro[3,2-e]imidazo[1,2-c]pyrimidin-2(3H)-one (3). Compound 2 also reacts with benzon

Structure-based design of novel Chk1 inhibitors: Insights into hydrogen bonding and protein-ligand affinity

We report the discovery, synthesis, and crystallographic binding mode of novel furanopyrimidine and pyrrolopyrimidine inhibitors of the Chk1 kinase, an oncology target. These inhibitors are synthetically tractable and inhibit Chk1 by competing for its ATP